CardieX Limited announced sales results for the first quarter September 2023. In the September quarter the Company has recorded unaudited revenue of $1.36 million (compared to $0.56 million in first quarter of fiscal year 2022), which is a year-on-year growth of 143% across Company's traditional business, with the sales and lease of Company's XCEL and Oscar 2 devices to pharmaceutical companies, research institutions, and specialist clinicians.